nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Infusion site reaction—Docetaxel—melanoma	0.0655	0.0655	CcSEcCtD
Oritavancin—Induration—Bleomycin—melanoma	0.0404	0.0404	CcSEcCtD
Oritavancin—Extravasation—Bleomycin—melanoma	0.0207	0.0207	CcSEcCtD
Oritavancin—Abscess—Carmustine—melanoma	0.0199	0.0199	CcSEcCtD
Oritavancin—Extravasation—Dactinomycin—melanoma	0.0193	0.0193	CcSEcCtD
Oritavancin—Eosinophilia—Vemurafenib—melanoma	0.0185	0.0185	CcSEcCtD
Oritavancin—Extravasation—Carmustine—melanoma	0.0181	0.0181	CcSEcCtD
Oritavancin—Wheezing—Bleomycin—melanoma	0.0175	0.0175	CcSEcCtD
Oritavancin—Infestation NOS—Vemurafenib—melanoma	0.0167	0.0167	CcSEcCtD
Oritavancin—Infestation—Vemurafenib—melanoma	0.0167	0.0167	CcSEcCtD
Oritavancin—Oedema peripheral—Vemurafenib—melanoma	0.0147	0.0147	CcSEcCtD
Oritavancin—Connective tissue disorder—Vemurafenib—melanoma	0.0147	0.0147	CcSEcCtD
Oritavancin—Erythema multiforme—Vemurafenib—melanoma	0.0141	0.0141	CcSEcCtD
Oritavancin—Cardiac disorder—Vemurafenib—melanoma	0.0139	0.0139	CcSEcCtD
Oritavancin—Mediastinal disorder—Vemurafenib—melanoma	0.0135	0.0135	CcSEcCtD
Oritavancin—Malnutrition—Vemurafenib—melanoma	0.013	0.013	CcSEcCtD
Oritavancin—Extravasation—Docetaxel—melanoma	0.0116	0.0116	CcSEcCtD
Oritavancin—Bronchospasm—Bleomycin—melanoma	0.0111	0.0111	CcSEcCtD
Oritavancin—Myalgia—Vemurafenib—melanoma	0.0111	0.0111	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.011	0.011	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.011	0.011	CcSEcCtD
Oritavancin—Blood bilirubin increased—Docetaxel—melanoma	0.0107	0.0107	CcSEcCtD
Oritavancin—Infection—Vemurafenib—melanoma	0.0106	0.0106	CcSEcCtD
Oritavancin—Nervous system disorder—Vemurafenib—melanoma	0.0104	0.0104	CcSEcCtD
Oritavancin—Skin disorder—Vemurafenib—melanoma	0.0103	0.0103	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Temozolomide—melanoma	0.00995	0.00995	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Temozolomide—melanoma	0.00975	0.00975	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00968	0.00968	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Vemurafenib—melanoma	0.00918	0.00918	CcSEcCtD
Oritavancin—Infestation NOS—Temozolomide—melanoma	0.00852	0.00852	CcSEcCtD
Oritavancin—Infestation—Temozolomide—melanoma	0.00852	0.00852	CcSEcCtD
Oritavancin—Erythema multiforme—Dactinomycin—melanoma	0.00799	0.00799	CcSEcCtD
Oritavancin—Hypersensitivity—Vemurafenib—melanoma	0.00783	0.00783	CcSEcCtD
Oritavancin—Oedema peripheral—Carmustine—melanoma	0.00779	0.00779	CcSEcCtD
Oritavancin—Connective tissue disorder—Carmustine—melanoma	0.00778	0.00778	CcSEcCtD
Oritavancin—Oedema peripheral—Temozolomide—melanoma	0.00753	0.00753	CcSEcCtD
Oritavancin—Pruritus—Vemurafenib—melanoma	0.00752	0.00752	CcSEcCtD
Oritavancin—Connective tissue disorder—Temozolomide—melanoma	0.00751	0.00751	CcSEcCtD
Oritavancin—Anaemia—Bleomycin—melanoma	0.00729	0.00729	CcSEcCtD
Oritavancin—Diarrhoea—Vemurafenib—melanoma	0.00727	0.00727	CcSEcCtD
Oritavancin—Erythema multiforme—Temozolomide—melanoma	0.00723	0.00723	CcSEcCtD
Oritavancin—Cardiac disorder—Temozolomide—melanoma	0.0071	0.0071	CcSEcCtD
Oritavancin—Dizziness—Vemurafenib—melanoma	0.00703	0.00703	CcSEcCtD
Oritavancin—Immune system disorder—Temozolomide—melanoma	0.00691	0.00691	CcSEcCtD
Oritavancin—Mediastinal disorder—Temozolomide—melanoma	0.00689	0.00689	CcSEcCtD
Oritavancin—Malnutrition—Carmustine—melanoma	0.00689	0.00689	CcSEcCtD
Oritavancin—Anaemia—Dactinomycin—melanoma	0.0068	0.0068	CcSEcCtD
Oritavancin—Vomiting—Vemurafenib—melanoma	0.00676	0.00676	CcSEcCtD
Oritavancin—Myalgia—Bleomycin—melanoma	0.00672	0.00672	CcSEcCtD
Oritavancin—Rash—Vemurafenib—melanoma	0.0067	0.0067	CcSEcCtD
Oritavancin—Dermatitis—Vemurafenib—melanoma	0.0067	0.0067	CcSEcCtD
Oritavancin—Headache—Vemurafenib—melanoma	0.00666	0.00666	CcSEcCtD
Oritavancin—Malnutrition—Temozolomide—melanoma	0.00666	0.00666	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Docetaxel—melanoma	0.00662	0.00662	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Docetaxel—melanoma	0.00648	0.00648	CcSEcCtD
Oritavancin—Infection—Bleomycin—melanoma	0.0064	0.0064	CcSEcCtD
Oritavancin—Anaemia—Carmustine—melanoma	0.00637	0.00637	CcSEcCtD
Oritavancin—Nausea—Vemurafenib—melanoma	0.00631	0.00631	CcSEcCtD
Oritavancin—Myalgia—Dactinomycin—melanoma	0.00627	0.00627	CcSEcCtD
Oritavancin—Bronchospasm—Docetaxel—melanoma	0.00625	0.00625	CcSEcCtD
Oritavancin—Anaemia—Temozolomide—melanoma	0.00615	0.00615	CcSEcCtD
Oritavancin—Angioedema—Temozolomide—melanoma	0.00608	0.00608	CcSEcCtD
Oritavancin—Infection—Dactinomycin—melanoma	0.00597	0.00597	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Bleomycin—melanoma	0.00587	0.00587	CcSEcCtD
Oritavancin—Myalgia—Carmustine—melanoma	0.00586	0.00586	CcSEcCtD
Oritavancin—Myalgia—Temozolomide—melanoma	0.00567	0.00567	CcSEcCtD
Oritavancin—Infestation NOS—Docetaxel—melanoma	0.00566	0.00566	CcSEcCtD
Oritavancin—Infestation—Docetaxel—melanoma	0.00566	0.00566	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00563	0.00563	CcSEcCtD
Oritavancin—Infection—Carmustine—melanoma	0.00558	0.00558	CcSEcCtD
Oritavancin—Tachycardia—Carmustine—melanoma	0.00549	0.00549	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00547	0.00547	CcSEcCtD
Oritavancin—Infection—Temozolomide—melanoma	0.0054	0.0054	CcSEcCtD
Oritavancin—Nervous system disorder—Temozolomide—melanoma	0.00533	0.00533	CcSEcCtD
Oritavancin—Skin disorder—Temozolomide—melanoma	0.00528	0.00528	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Carmustine—melanoma	0.00512	0.00512	CcSEcCtD
Oritavancin—Urticaria—Bleomycin—melanoma	0.00512	0.00512	CcSEcCtD
Oritavancin—Oedema peripheral—Docetaxel—melanoma	0.00501	0.00501	CcSEcCtD
Oritavancin—Connective tissue disorder—Docetaxel—melanoma	0.005	0.005	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Temozolomide—melanoma	0.00495	0.00495	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Carmustine—melanoma	0.00485	0.00485	CcSEcCtD
Oritavancin—Erythema multiforme—Docetaxel—melanoma	0.00481	0.00481	CcSEcCtD
Oritavancin—Hypersensitivity—Bleomycin—melanoma	0.00474	0.00474	CcSEcCtD
Oritavancin—Cardiac disorder—Docetaxel—melanoma	0.00472	0.00472	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Temozolomide—melanoma	0.00469	0.00469	CcSEcCtD
Oritavancin—Immune system disorder—Docetaxel—melanoma	0.00459	0.00459	CcSEcCtD
Oritavancin—Mediastinal disorder—Docetaxel—melanoma	0.00458	0.00458	CcSEcCtD
Oritavancin—Pruritus—Bleomycin—melanoma	0.00456	0.00456	CcSEcCtD
Oritavancin—Malnutrition—Docetaxel—melanoma	0.00443	0.00443	CcSEcCtD
Oritavancin—Hypersensitivity—Dactinomycin—melanoma	0.00443	0.00443	CcSEcCtD
Oritavancin—Urticaria—Temozolomide—melanoma	0.00432	0.00432	CcSEcCtD
Oritavancin—Hypersensitivity—Carmustine—melanoma	0.00414	0.00414	CcSEcCtD
Oritavancin—Diarrhoea—Dactinomycin—melanoma	0.00411	0.00411	CcSEcCtD
Oritavancin—Vomiting—Bleomycin—melanoma	0.00409	0.00409	CcSEcCtD
Oritavancin—Anaemia—Docetaxel—melanoma	0.00409	0.00409	CcSEcCtD
Oritavancin—Rash—Bleomycin—melanoma	0.00406	0.00406	CcSEcCtD
Oritavancin—Dermatitis—Bleomycin—melanoma	0.00406	0.00406	CcSEcCtD
Oritavancin—Hypersensitivity—Temozolomide—melanoma	0.004	0.004	CcSEcCtD
Oritavancin—Diarrhoea—Carmustine—melanoma	0.00385	0.00385	CcSEcCtD
Oritavancin—Pruritus—Temozolomide—melanoma	0.00384	0.00384	CcSEcCtD
Oritavancin—Nausea—Bleomycin—melanoma	0.00383	0.00383	CcSEcCtD
Oritavancin—Vomiting—Dactinomycin—melanoma	0.00382	0.00382	CcSEcCtD
Oritavancin—Rash—Dactinomycin—melanoma	0.00379	0.00379	CcSEcCtD
Oritavancin—Myalgia—Docetaxel—melanoma	0.00377	0.00377	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00374	0.00374	CcSEcCtD
Oritavancin—Dizziness—Carmustine—melanoma	0.00372	0.00372	CcSEcCtD
Oritavancin—Diarrhoea—Temozolomide—melanoma	0.00372	0.00372	CcSEcCtD
Oritavancin—Dizziness—Temozolomide—melanoma	0.00359	0.00359	CcSEcCtD
Oritavancin—Infection—Docetaxel—melanoma	0.00359	0.00359	CcSEcCtD
Oritavancin—Vomiting—Carmustine—melanoma	0.00357	0.00357	CcSEcCtD
Oritavancin—Nausea—Dactinomycin—melanoma	0.00357	0.00357	CcSEcCtD
Oritavancin—Rash—Carmustine—melanoma	0.00354	0.00354	CcSEcCtD
Oritavancin—Nervous system disorder—Docetaxel—melanoma	0.00354	0.00354	CcSEcCtD
Oritavancin—Dermatitis—Carmustine—melanoma	0.00354	0.00354	CcSEcCtD
Oritavancin—Tachycardia—Docetaxel—melanoma	0.00353	0.00353	CcSEcCtD
Oritavancin—Headache—Carmustine—melanoma	0.00352	0.00352	CcSEcCtD
Oritavancin—Skin disorder—Docetaxel—melanoma	0.00351	0.00351	CcSEcCtD
Oritavancin—Vomiting—Temozolomide—melanoma	0.00345	0.00345	CcSEcCtD
Oritavancin—Rash—Temozolomide—melanoma	0.00343	0.00343	CcSEcCtD
Oritavancin—Dermatitis—Temozolomide—melanoma	0.00342	0.00342	CcSEcCtD
Oritavancin—Headache—Temozolomide—melanoma	0.0034	0.0034	CcSEcCtD
Oritavancin—Nausea—Carmustine—melanoma	0.00334	0.00334	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Docetaxel—melanoma	0.00329	0.00329	CcSEcCtD
Oritavancin—Nausea—Temozolomide—melanoma	0.00323	0.00323	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Docetaxel—melanoma	0.00312	0.00312	CcSEcCtD
Oritavancin—Hypersensitivity—Docetaxel—melanoma	0.00266	0.00266	CcSEcCtD
Oritavancin—Pruritus—Docetaxel—melanoma	0.00256	0.00256	CcSEcCtD
Oritavancin—Diarrhoea—Docetaxel—melanoma	0.00247	0.00247	CcSEcCtD
Oritavancin—Dizziness—Docetaxel—melanoma	0.00239	0.00239	CcSEcCtD
Oritavancin—Vomiting—Docetaxel—melanoma	0.0023	0.0023	CcSEcCtD
Oritavancin—Rash—Docetaxel—melanoma	0.00228	0.00228	CcSEcCtD
Oritavancin—Dermatitis—Docetaxel—melanoma	0.00228	0.00228	CcSEcCtD
Oritavancin—Headache—Docetaxel—melanoma	0.00226	0.00226	CcSEcCtD
Oritavancin—Nausea—Docetaxel—melanoma	0.00215	0.00215	CcSEcCtD
